---
title: "Lipocine raises its at-the-market program to $50,000,000"
url: "https://aibio.space/news/lipocine-raises-market-program-50-000-000/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2026-02-26"
section: "Financings"
tickers: "NASDAQ:LPCN"
source: "https://www.sec.gov/Archives/edgar/data/1535955/000149315226008201/form424b5.htm"
summary: "Lipocine Inc. filed a prospectus supplement on February 26, 2026 under its sales agreement with A.G.P./Alliance Global Partners. It had sold $10,615,576 of"
---

By the aibio.space news desk.

Sources

- [Lipocine Inc. 424B5 (2026-02-26)](https://www.sec.gov/Archives/edgar/data/1535955/000149315226008201/form424b5.htm)
- [Lipocine Inc. 8-K (2026-03-04)](https://www.sec.gov/Archives/edgar/data/1535955/000149315226008852/form8-k.htm)

[LPCN](https://aibio.space/companies/lipocine/)

2026-02-26

# Lipocine raises its at-the-market program to $50,000,000

Tickers [LPCN](https://aibio.space/companies/lipocine/)

Lipocine Inc. filed a prospectus supplement on February 26, 2026 under its sales agreement with A.G.P./Alliance Global Partners. It had sold $10,615,576 of stock under the earlier registration.

## Key facts

- **Company**: Lipocine Inc. (NASDAQ: LPCN)

- **News type**: Financings

- **Primary source**: [Lipocine Inc. 424B5 (2026-02-26)](https://www.sec.gov/Archives/edgar/data/1535955/000149315226008201/form424b5.htm)

*A meeting room with a long table and a screen. CC0, via rawpixel. The picture shows the field, not the companies named.*

Lipocine Inc. (Nasdaq: [LPCN](https://aibio.space/companies/lipocine/)) filed a prospectus supplement on February 26, 2026 that increases the amount of common stock it may sell under its sales agreement with A.G.P./Alliance Global Partners. The agreement is dated April 26, 2024. The new total is up to an aggregate of $50,000,000, including shares already sold.

Under the earlier prospectus, Lipocine had registered up to an aggregate of $10,616,169 of common stock. The company said that from April 26, 2024 through the date of the new supplement, it sold 1,603,431 shares for an aggregate purchase price of $10,615,576. From the date of the supplement, the amount that remains available is $39,384,424.

An at-the-market program like this lets a company sell shares gradually through an agent at prevailing market prices. A.G.P. is the sales agent.

Lipocine later disclosed the supplement in a Form 8-K dated March 4, 2026. The shares are offered under a registration statement on Form S-3.

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

LPCN

Lipocine Inc.

NASDAQ · United States

Open the starter desk

## More in Financings

Financings

### [INmune Bio raises $4.50 million in registered direct offering with warrants](https://aibio.space/news/inmune-bio-raises-4-50-million-registered-direct-offering-warrants/)

Oct 29, 2026

Financings

### [Lexeo Therapeutics files $300 million shelf registration](https://aibio.space/news/lexeo-therapeutics-files-300-million-shelf-registration/)

Oct 29, 2026

Financings

### [ProKidney files $650 million shelf with $200 million Jefferies sales program](https://aibio.space/news/prokidney-files-650-million-shelf-200-million-jefferies-sales-program/)

Oct 29, 2026

---
Source page: https://aibio.space/news/lipocine-raises-market-program-50-000-000/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Lipocine raises its at-the-market program to $50,000,000", 2026-02-26, https://aibio.space/news/lipocine-raises-market-program-50-000-000/